The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer's disease

Manuscript Number:

14-3090R2

Author(s):

Pernille Barkholt, Katrine Fabricius, Susan A. Farr, Henrik H. Hansen, Jacob Jelsing, Lotte Bjerre Knudsen, John E. Morley, Michael L. Niehoff, Charles Pyke, Niels Vrang

Disclosures

Pernille Barkholt

Nothing to Disclose

Katrine Fabricius

Nothing to Disclose

Susan A. Farr

Grants
- Agency:
  Novo Nordisk
  Dates:
  1/1/12 - 12-31-12

Henrik H. Hansen

Nothing to Disclose

Jacob Jelsing

Equity:
I am co-owner of Gubra

Patents/Royalties
Gubra is a CRO in the metabolic area

Lotte Bjerre Knudsen

Equity:
I am a full time employee of Novo Nordisk who markets liraglutide for the treatment of diabetes and obesity, and own a small number of shares as part of my salary.

Sponsors:
I am a full time employee of Novo Nordisk who markets liraglutide for the treatment of diabetes and obesity

Patents/Royalties
i am inventor on patent but with absolutely no financial gain for me, all patents belong to the company i work for, and i get no royalties.

John E. Morley

Consulting Fees:
Sonafi-Aventis, Nutricia, Astellas, Boehringer-Ingelheim, Merck and Akros

Lecture Fees:
Nutricia Speaker's Bureau
Grants
- Agency:
  Nestle (Purina)
  Dates:
  2008-present
- Agency:
  Kemin
  Dates:
  2012-present

Michael L. Niehoff

Nothing to Disclose

Charles Pyke

Equity:
Author is full-time employee of Novo Nordisk A/S, which markets liraglutide for the treatment of diabetes and hold minor stock portions as part of an employee offering program

Sponsors:
Author is full-time employee of Novo Nordisk A/S, which markets liraglutide for the treatment of diabetes and hold minor stock portions as part of an employee offering program

Niels Vrang

Consulting Fees:
Consulting for NovoNordisk in relation to Liraglutide and obesity.